Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.
TONMYA's market access has expanded considerably, with coverage now representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to reach approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. The strong prescription trends and expanding coverage underscore the commercial potential of TONMYA, which is the first new treatment for fibromyalgia in over 15 years.
Beyond commercial performance, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments highlight the company's commitment to addressing high unmet medical needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial position provides a runway to support ongoing commercial efforts and clinical trials.
The strong revenue growth and pipeline progress are important for investors as they indicate that Tonix is transitioning from a development-stage company to a commercial-stage entity with multiple growth drivers. The success of TONMYA is critical, as it establishes a revenue base and validates the company's commercial infrastructure, which also supports its acute migraine products, Zembrace SymTouch and Tosymra.
Tonix's broader pipeline includes TNX-2900 for Prader-Willi syndrome, a rare disease, and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These programs, along with the ongoing studies for TONMYA in major depressive disorder and acute stress disorder, provide additional upside potential.
Investors should note that the company's product development candidates are investigational and have not been approved for any indication. However, the recent commercial achievements and pipeline advancements position Tonix for continued growth. For more information, visit the company's newsroom at https://ibn.fm/TNXP.
